Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.47 |
| ▸ | LIPE | Q05469 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1677131 | 0.95 | ALDH1A1 (0.48) | POLBALDH1A1TP53NAMPTEPHX2 | |
| SCHEMBL1677129 | 0.95 | ALDH1A1 (0.48) | POLBALDH1A1TP53NAMPTEPHX2 | |
| SCHEMBL1677033 | 0.92 | PKM (0.54) | POLBALDH1A1EPHX2EPHX1KMT2A | |
| SCHEMBL1677174 | 0.86 | EPHX2 (0.63) | ALDH1A1NAMPTEPHX2EPHX1MEN1 | |
| SCHEMBL1677127 | 0.85 | EPHX2 (0.53) | EPHX2EPHX1MEN1KMT2APKM | |
| SCHEMBL1677090 | 0.85 | EPHX2 (0.52) | ALDH1A1EPHX2EPHX1MEN1KMT2A | |
| SCHEMBL1677124 | 0.84 | EPHX2 (0.52) | EPHX2EPHX1LIPE | |
| SCHEMBL1677213 | 0.84 | EPHX2 (0.53) | EPHX2EPHX1MEN1KMT2APKM | |
| SCHEMBL1677133 | 0.84 | EPHX2 (0.52) | EPHX2EPHX1MEN1KMT2ALIPE | |
| SCHEMBL1677009 | 0.83 | EPHX2 (0.58) | POLBALDH1A1EPHX2EPHX1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518934-B2 | Oxycarbamoyl compounds and the use thereof | SHONOGI & CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-2346820-B1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO (JP) | 2013-02-13 | — | — | EP | disclosed |
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2011-04-28 | — | — | US | disclosed |
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | CACNA1B, ORAI1, CACNA1I | POLB 4191/4885ALDH1A1 2177/4885TP53 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.